How to Cite
Abstract
CREATION OF NEW DRUG COMPOSITIONS AND PHARMACOLOGICAL SUBSTANTIATION OF THEIR SUITABILITY FOR PAIN SYNDROMES AND INFLAMMATIONS IN EXPERIMENTAL RATS
Syrovaya A.O., Bachinskiy R.O., Grabovetskaya E.R.
Kharkiv national medical university, Kharkiv, Ukraine
Abstract. Creation of combined drugs whose pharmacological effects are due to the rational combination of ingredients is the urgent problem of modern medicine. Combination of several components in one drug expands its pharmacological range and promotes polytropic activity. The advantage of combined drugs compared with pure drugs is that they more effectively eliminate pain and inflammation than each individual component.
Combined analgesics often include caffeine. According to literature data caffeine enhances analgesic effect of nonsteroidal anti-inflammatory drugs (NSAIDs) and nonnarcotic analgesics (NNA). However, there are no data on the composition of diclofenac sodium (D-Na), ibuprofen (Ib) with caffeine in the literature. This fact caused experimental studies of influence of caffeine on the analgesic and anti-exudative effects of D-Na and Ib. Experimental studies have been conducted on laboratory animals (white adult rats of the WAG strain) by intragastric administration. Analysis of experimental results clearly indicates that caffeine potentiates analgesic and anti-exudative effects of D-Na and Ib.
Thus, compositions of D-Na and Ib with caffeine were experimentally studied for the first time. Suitability of compositions is proved and application in inflammation and pain of various origins is demonstrated. Results can serve as foundation for development of new domestic combined drugs with analgesic and anti-inflammatory effects.
Keywords: non-steroidal anti-inflammatory drugs, ibuprofen, diclofenac sodium, caffeine, analgesic activity, anti-inflammatory activity, CNS.
СТВОРЕННЯ НОВИХ ЛІКАРСЬКИХ КОМПОЗИЦІЙ ТА ФАРМАКОЛОГІЧНЕ ОБҐРУНТУВАННЯ ЇХ ДОЦІЛЬНОСТІ ПРИ БОЛЬОВИХ СИНДРОМАХ І ЗАПАЛЬНИХ ПРОЦЕСАХ В ЕКСПЕРИМЕНТІ НА ЩУРАХ
Г. О. Сирова, Р. О. Бачинський, Є. Р. Грабовецька
Харківський національний медичний університет, м. Харків, Україна
Резюме. Нагальною проблемою на сучасному етапі розвитку медицини є створення комбінованих лікарських засобів, фармакологічні ефекти яких досягаються завдяки раціональній комбінації інгредієнтів. Комбінація в одному лікарському препараті кількох компонентів розширює його фармакологічний спектр і сприяє політропній дії. Перевага комбінованих лікарських препаратів порівняно з монопрепаратами полягає у тому, що вони ефективніше ліквідують біль, запалення, ніж кожний окремий компонент.
Часто до складу комбінованих протибольових засобів входить кофеїн, який за літературними даними може підсилювати протибольову дію нестероїдних протизапальних засобів (НПЗЗ) та ненаркотичних анальгетиків (ННА). Але дані про наявність композиції диклофенак-натрію (D-Na), ібупрофену (Ib) з кофеїном у літературі відсутні. Це послужило поштовхом для проведення експериментальних досліджень по вивченню впливу кофеїну на протибольову та антиексудативну дію D-Na та Ib. Експериментальні дослідження були проведені на лабораторних тваринах (статевозрілі білі щури лінії WAG) при внутрішньошлунковому введенні. Аналіз результатів експериментальних досліджень переконливо свідчить, що кофеїн потенціює протибольову та антиексудативну дію D-Na та Ib.
Таким чином, вперше було експериментально досліджено композиції кофеїну з D-Na та Ib, обґрунтовано їх доцільність, доведено їх застосування при запаленні та болі різного ґенезу. Результати дослідження можуть стати фундаментом для розробки нових вітчизняних комбінованих лікарських засобів з протибольовою та протизапальною дією.
Ключові слова: нестероїдні протизапальні засоби, ібупрофен, диклофенак-натрію, кофеїн, протибольова дія, протизапальна дія, ЦНС.
СОЗДАНИЕ НОВЫХ ЛЕКАРСТВЕННЫХ КОМПОЗИЦИЙ И ФАРМАКОЛОГИЧЕСКОЕ ОБОСНОВАНИЕ ИХ ЦЕЛЕСООБРАЗНОСТИ ПРИ БОЛЕВЫХ СИНДРОМАХ И ВОСПАЛИТЕЛЬНЫХ ПРОЦЕССАХ В ЭКСПЕРИМЕНТЕ НА КРЫСАХ
А. О. Сыровая, Р. О. Бачинский, Е. Р. Грабовецкая
Харьковский национальный медицинский университет, г. Харьков, Украина
Резюме. Неотложной проблемой на современном этапе развития медицины является создание комбинированных лекарственных средств, фармакологические эффекты которых достигаются благодаря рациональной комбинации ингредиентов. Комбинация в одном лекарственном препарате нескольких компонентов расширяет его фармакологический спектр и способствует политропному действию. Преимущество комбинированных лекарственных препаратов по сравнению с монопрепаратами заключается в том, что они эффективнее ликвидируют боль, воспаление, чем каждый отдельный компонент.
Часто в состав комбинированных противоболевых средств входит кофеин, который, согласно литературным данным, может усиливать противоболевое действие нестероидных противовоспалительных средств (НПВС) и ненаркотических анальгетиков (ННА). Но данные о существовании композиции диклофенак-натрия (D-Na), ибупрофена (Ib) с кофеином в литературе отсутствуют. Это послужило толчком для проведения экспериментальных исследований по изучению влияния кофеина на противоболевое и антиэкссудативное действие D-Na и Ib. Экспериментальные исследования были проведены на лабораторных животных (половозрелые белые крысы линии WAG) при внутрижелудочном введении. Анализ результатов экспериментальных исследований убедительно свидетельствует, что кофеин потенцирует противоболевое и антиэкссудативное действие D-Na и Ib.
Таким образом, впервые экспериментально исследованы композиции кофеина с D-Na и Ib, обоснована их целесообразность, доказано их применение при воспалении и боли различного генеза. Результаты исследования могут стать фундаментом для разработки новых отечественных комбинированных лекарственных средств с противоболевым и противовоспалительным действием.
Ключевые слова: нестероидные противовоспалительные средства, ибупрофен, диклофенак-натрия, кофеин, противоболевое действие, противовоспалительное действие, ЦНС.
References
Дослідження квантово-фармакологічних властивостей молекули карбамазепіну / Г. О. Сирова, Т. Ю. Небесна, Т. В. Звягінцева, І. С. Чекман // Фармакологія та лікарська токсикологія. – 2008. – № 5–6. – С. 25–26. [Study of quantum-pharmacological properties of carbamazepine molecule / A. O. Syrovaya, T. Yu. Nebesnaya, T. V. Zviaginceva, I. S. Chekman // Pharmacologiya ta likarska toksicologiya. – 2008. – № 5–6. – P. 25–26. (In Ukr.)]
Кофеїн: Фізіологічні, біохімічні та квантово-фармакологічні властивості / І. Чекман, Н. Горчакова, Т. Звягінцева, Г. Сирова, Н. Небесна // Вісник фармакології та фармації. – 2009. – № 6. – С. 2–7.[Caffeine: physiological, biochemical and quantum-pharmacological properties / I. Chekman, N. Gorchakova, T. Zviaginceva, A. Syrovaya, T. Nebesnaya // Visnyk pharmacologii ta pharmacii. – 2009. – № 6. – P. 2–7. (In Ukr.)]
Насонова В. А. Рациональное применение НПВП в ревматологии / В. А. Насонова // Русский медицинский журнал. –2002. – Т 10, № 6. – С. 302–306.[Nasonova V. A. Rational application of NSAIDs in rheumatology // Russkiy medicinskiy journal. –2002. – Vol. 10, № 6. – P. 302–306. (In Russ.)]
Насонов Е. Л. Гастропатия, связанная с приемом нестероидных противовоспалительных препаратов (Часть 1) / Е. Л. Насонов, А. Е. Каратеев // Клин. медицина. – 2000. – Т. 78, № 3. – С. 4–10. [Nasonov E. L., Karateev A. E. Gastropathy associated with nonsteroidal anti-inflammatory drugs administration (Part 1) // Klin. medicina. – 2000. – Vol. 78, № 3. – P. 4–10. (In Russ.)]
Efficacy and tolerability of aceclofenac vs. diclofenac in the treatment of knee osteoarthritis. A multicenter stady / С. Diaz, A. Rodriques, С. Geli [et al.] // Eur. J. Rheumatol. Inflam. – 1996. – № 16. – Р. 17–22.
Variability in risk of gastrointestinal complications with individual NSAIDs: results of a collaborative meta-analysis / D. Henry, L. Lim, L. Garia Rodriquez [et al.] // Br. Med. J. – 1996. – № 312. – Р. 1563–1566.
Rainsford K. D. Discovery, mechanisms of action and safety of ibuprofen / K. D. Rainsford // Int. J. Clin. Pract. Suppl. – 2003. – № 135. – Р. 3–8.
Gotzsche P. C. Non-steroidal anti-inflammatory drugs. Extracts from «Clinical Evidence» / P. C. Gotzsche // Br. Med. J. – 2000. – № 320. – Р. 1058–1061.
Beaver W. T. Review of the analgesic efficacy of ibuprofen / W. T. Beaver // Int. J. Clin. Pract. Suppl. – 2003. – № 135. – Р. 13–17.
Доклінічні дослідження лікарських засобів: метод. рек. / за ред. О.В. Стефанова. – К., 2001. – 527 с. [Preclinical studies of drugs: methodical recommendations / edited by O. V. Stefanov. – Кiev: 2001. – 527 p. (In Ukr.)]
Гланц С. Медико–биологическая статистика / С. Гланц; пер. с англ. – М.: Практика, 1998. – 459 с. [Glanc S. Medico-biological statistics. – Moscow: Practica, 1998. – 459 p. (In Russ.)]
European convention for the protection of vertebrate animals used for experimental and other scientific purposes // Council of European. – Strasbourg, 1986. – № 123. – 51 p.
"Inter Collegas" is an open access journal: all articles are published in open access without an embargo period, under the terms of the CC BY-NC-SA (Creative Commons Attribution ‒ Noncommercial ‒ Share Alike) license; the content is available to all readers without registration from the moment of its publication. Electronic copies of the archive of journals are placed in the repositories of the KhNMU and V.I. Vernadsky National Library of Ukraine.
Copyright Agreement
1. This Agreement on the transfer of rights to use the work from the Co-authors to the publisher (hereinafter the Agreement) is concluded between all the Co-authors of the work, represented by the Corresponding Author, and Kharkiv National Medical University (hereinafter the University), represented by an authorized representative of the Editorial Board of scientific journals (hereinafter the Editorial Board).
2. This Agreement is an accession agreement within the meaning of clause 1 of Article 634 of the Civil Code of Ukraine: that is, a contract, "the terms of which are established by one of the parties in forms or other standard forms, which can be concluded only by joining the other party to the proposed contract as a whole. The other party cannot offer its terms of the contract." The party that established the terms of this contract is the University.
3. If there is more than one author, the authors choose the Corresponding Author, who communicates with the Editorial Board on his own behalf and on behalf of all Co-authors regarding the publication of a written work of a scientific nature (article or review, hereinafter referred to as the Work).
4. The contract begins from the moment of submission of the manuscript of the Work by the Corresponding Author to the Editorial Board, which confirms the following:
4.1. all Co-authors of the Work are familiar with and agree with its content, at all stages of reviewing and editing the manuscript and the existence of the published Work;
4.2. all Co-authors of the Work are familiar with and agree to the terms of this Agreement.
5. The published Work is in electronic form in public access on the websites of the University and any websites and electronic databases in which the Work is posted by the University and is available to readers under the terms of the "Creative Commons" license (Attribution NonCommercial Sharealike 4.0 International)" or more free licenses "Creative Commons 4.0".
6. The Corresponding Author transfers, and the University receives, the non-exclusive property right to use the Work by placing the latter on the University's websites for the entire term of copyright. The University participates in the creation of the final version of the Work by reviewing and editing the manuscript of the article or review provided to the Editorial Board by the Corresponding Author, translating the Work into any languages. For the participation of the University in the finalization of the Work, the Co-authors agree to pay the invoice issued to them by the University, if such payment is provided by the University. The size and procedure of such payment are not the subject of this contract.
7. The University has the right to reproduce the Work or its parts in electronic and printed forms, to make copies, permanent archival storage of the Work, distribution of the Work on the Internet, repositories, scientometric databases, commercial networks, including for monetary compensation from third parties.
8. The co-authors guarantee that the manuscript of the Work does not use works whose copyright belongs to third parties.
9. The authors of the Work guarantee that at the time of submission of the manuscript of the Work to the Editorial Board, the property rights to the Work belong only to them, neither in whole nor in part have they been transferred to anyone (not alienated), they are not the subject of a lien, litigation or claims by third parties.
10. The Work may not be posted on the University's website if it violates a person's right to the privacy of his personal and family life, harms public order and health.
11. The work may be withdrawn by the Editorial Board from the University websites, libraries and electronic databases where it was placed by the Editorial Board, in cases of detection of violations of the ethics of the authors and researchers, without any compensation for the losses of the Co-authors. At the time of submission of the manuscript to the Editorial Board and all stages of its editing and review, the manuscript must not have already been published or submitted to other editorial offices.
12. The right transferred under this Agreement extends to the territory of Ukraine and foreign countries.
13. The rights of Co-authors include the requirement to indicate their names on all copies of the Work or during any public use or public mention of the Work; the requirement to preserve the integrity of the Work; legal opposition to any distortion or other encroachment on the Work, which may harm the honor and reputation of the Co-authors.
14. Co-authors have the right to control their personal non-property rights by familiarizing themselves with the text (content) and form of the Work before its publication on the University's website, when transferring it to a printing company for reproduction or when using the Work in other ways.
15. The Co-authors, in addition to the property rights not transferred under this Agreement and taking into account the non-exclusive nature of the rights transferred under this Agreement, retain the property rights to finalize the Work and to use certain parts of the Work in other works created by the Co-authors.
16. The Co-authors are obliged to notify the Editorial Board of all errors in the Work, discovered by them independently after the publication of the Work, and to take all measures to eliminate such errors as soon as possible.
17. The University undertakes to indicate the names of the Co-authors on all copies of the Work during any public use of the Work. The list of Co-authors may be shortened according to the rules for the formation of bibliographic descriptions determined by the University or third parties.
18. The University undertakes not to violate the integrity of the Work, to agree with the Corresponding Author on all changes made to the Work during processing and editing.
19. In case of violation of their obligations under this Agreement, its parties bear the responsibility defined by this Agreement and the current legislation of Ukraine. All disputes under the Agreement are resolved through negotiations, and if the negotiations do not resolve the dispute – in the courts of the city of Kharkiv.
20. The parties are not responsible for the violation of their obligations under this Agreement, if it occurred through no fault of theirs. The party is considered innocent if it proves that it has taken all measures dependent on it for the proper fulfillment of the obligation.
21. The Co-authors are responsible for the truthfulness of the facts, quotes, references to legislative and regulatory acts, other official documentation, the scientific validity of the Work, all types of responsibility to third parties who have claimed their rights to the Work. The co-authors reimburse the University for all costs caused by claims of third parties for infringement of copyright and other rights to the Work, as well as additional material costs related to the elimination of identified defects.